1-8 of 8
Juraj Koska
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Relationship of Plasma Apolipoprotein C-I Truncation With Risk of Diabetes in the Multi-Ethnic Study of Atherosclerosis and the Actos Now for the Prevention of Diabetes Study

Juraj Koska, Yueming Hu, Jeremy Furtado, Dean Billheimer, Dobrin Nedelkov, Dawn Schwenke, Matthew J. Budoff, Alain G. Bertoni, Robyn L. McClelland, Peter D. Reaven
Journal: Diabetes Care
Diabetes Care 2024;47(12):2214–2222
https://doi.org/10.2337/dc24-1462
Published: 25 October 2024
View article titled, Relationship of Plasma Apolipoprotein C-I Truncation With Risk of Diabetes in the Multi-Ethnic Study of Atherosclerosis and the Actos Now for the Prevention of Diabetes Study
Open the PDF for Relationship of Plasma Apolipoprotein C-I Truncation With Risk of Diabetes in the Multi-Ethnic Study of Atherosclerosis and the Actos Now for the Prevention of Diabetes Study in another window
Journal Articles

Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684–691

Juraj Koska, Hertzel C. Gerstein, Paul J. Beisswenger, Peter D. Reaven
Journal: Diabetes Care
Diabetes Care 2022;45(6):e111–e112
https://doi.org/10.2337/dci22-0013
Published: 27 May 2022
View article titled, Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684–691
Open the PDF for Response to Comment on Koska et al. Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes. Diabetes Care 2022;44:684–691 in another window
Journal Articles

Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes

Juraj Koska, Hertzel C. Gerstein, Paul J. Beisswenger, Peter D. Reaven
Journal: Diabetes Care
Diabetes Care 2022;45(3):684–691
https://doi.org/10.2337/dc21-2196
Published: 20 January 2022
View article titled, Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes
Open the PDF for Advanced Glycation End Products Predict Loss of Renal Function and High-Risk Chronic Kidney Disease in Type 2 Diabetes in another window
Journal Articles

The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study

Juraj Koska, Raymond Q. Migrino, Keith C. Chan, Kelly Cooper-Cox, Peter D. Reaven
Journal: Diabetes Care
Diabetes Care 2021;44(6):1385–1392
https://doi.org/10.2337/dc20-2014
Published: 25 January 2021
View article titled, The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study
Open the PDF for The Effect of Exenatide Once Weekly on Carotid Atherosclerosis in Individuals With Type 2 Diabetes: An 18-Month Randomized Placebo-Controlled Study in another window
Journal Articles

Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT

Daniel S. Nuyujukian, Juraj Koska, Gideon Bahn, Peter D. Reaven, Jin J. Zhou
Journal: Diabetes Care
Diabetes Care 2020;43(7):1471–1478
https://doi.org/10.2337/dc19-2540
Published: 23 April 2020
View article titled, Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT
Open the PDF for Blood Pressure Variability and Risk of Heart Failure in ACCORD and the VADT in another window
Journal Articles

Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes

Juraj Koska, Aramesh Saremi, Scott Howell, Gideon Bahn, Barbora De Courten, Henry Ginsberg, Paul J. Beisswenger, Peter D. Reaven, for the VADT Investigators
Journal: Diabetes Care
Diabetes Care 2018;41(3):570–576
https://doi.org/10.2337/dc17-1740
Published: 05 December 2017
View article titled, Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes
Open the PDF for Advanced Glycation End Products, Oxidation Products, and Incident Cardiovascular Events in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT)

Juraj Koska, MD, Aramesh Saremi, MD, Gideon Bahn, PHD, Shizuya Yamashita, MD, Peter D. Reaven, MD, for the Veterans Affairs Diabetes Trial Investigators
Journal: Diabetes Care
Diabetes Care 2013;36(8):2408–2414
https://doi.org/10.2337/dc12-2082
Published: 11 July 2013
View article titled, The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT)
Open the PDF for The Effect of Intensive Glucose Lowering on Lipoprotein Particle Profiles and Inflammatory Markers in the Veterans Affairs Diabetes Trial (VADT) in another window
Includes: Supplementary data
Journal Articles

Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes

Juraj Koska, MD, Eric A. Schwartz, PHD, Michael P. Mullin, BS, Dawn C. Schwenke, PHD, Peter D. Reaven, MD
Journal: Diabetes Care
Diabetes Care 2010;33(5):1028–1030
https://doi.org/10.2337/dc09-1961
Published: 03 March 2010
View article titled, Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes
Open the PDF for Improvement of Postprandial Endothelial Function After a Single Dose of Exenatide in Individuals With Impaired Glucose Tolerance and Recent-Onset Type 2 Diabetes in another window
Includes: Supplementary data